

PHARMACY CHAIN 36.6 PUBLISHES FY2009 and Q4 TRADE UPDATE (UNAUDITED)

April 15, 2010, MOSCOW – OJSC Pharmacy Chain 36.6 [RTS:APTK; MICEX:RU14APTK1007], the leading Russian pharmaceutical retailer, announces FY2009 and Q4 2009 unaudited sales and operational results according to the management accounts.

GROUP SALES¹:

- Group's consolidated sales reached RUR 21 065.2 mln versus RUR 26 042.5 mln. in 2008, a 19.1% decrease in ruble terms y-o-y;
- Pharmacy Retail Sales reached RUR 15 988.6 mln versus RUR 20 837.2 mln in 2008, a 23.3% decrease in ruble terms y-o-y;
- Sales of finished goods of the production unit Veropharm increased by 2.2% in ruble terms and reached RUR 4 395.1 mln versus RUR 4 301.3 mln in 2008.
- Other non-core businesses decreased by 24.6% in ruble terms².

<i>Sales, mln</i>	Consolidated	Retail	Veropharm	Other
Q4 2009	5 029.3	3 622.2	1 179.9	227.2
Q4 2008	6 489.6	5 071.7	1 224.6	193.3
<i>Change y-o-y</i>	<i>-22.5%</i>	<i>-28.6%</i>	<i>-3.6%</i>	<i>17.5%</i>
FY 2009	21 065.2	15 988.6	4 395.1	681.5
FY 2008	26 042.5	20 837.2	4 301.3	904.0
<i>Change y-o-y</i>	<i>-19.1%</i>	<i>-23.3%</i>	<i>2.2%</i>	<i>-24.6%</i>

Valeria Solok, Chief Executive Officer of the Management Company "Pharmacy Chain 36.6":

"2009 was a turning year for Pharmacy Chain 36.6, difficulties with raising capital and decline in consumer demand led to the 23.3% decline in the Retail unit sales in 2009. However, we managed to restructure our long-term obligations, completely restore our relations with suppliers, reduce stock-out levels and optimize the Company in order to become efficient in the new economic environment. Positive changes already were obvious in Q4, and we saw a slow down in a sales decline rate. New strategy of the Company which among others includes revision of relations with suppliers, qualitative leap in our private label development, and formation of a unique product offering will allow us to increase traffic and achieve growth of the profitability indicators in 2010".

RETAIL:

- As of the end of Q4 2009, Pharmacy Chain 36.6 operated 1019 stores in 29 regions of Russia.
- During Q4 2009 5 stores were opened organically and 12 were closed (no stores were rebranded or reformatted).
- As of the end of Q4 2009, Pharmacy Chain 36.6 operated 13 ELC stores, 10 stand-alone optical outlets and 19 additional optical departments within pharmacies.

¹ Hereinafter – these financial indicators may vary from the consolidated financial reporting prepared in accordance with IFRS.

² 2008 results include operational results of the European medical center which was sold in May 2008.

As of 31.12.2009:

Business Unit	No. of pharmacies	Share of Sales	Ave. retail space per pharmacy, sq.m.
1. Moscow-Central	373	50.2%	74.9
<i>Northwest</i>	<i>24</i>	<i>3.1%</i>	<i>67.9</i>
2. South Urals	217	16.8%	57.4
3. South	163	12.8%	53.1
4. Volga	128	9.4%	55.6
5. North Urals	86	6.6%	55.2
6. Siberia	52	4.2%	53.0
Total:	1019	100%	62.5

OPERATIONAL DATA FOR THE RETAIL UNIT:

- In 2009 70.9 million purchases were made, which is 29.9% lower than in 2008.
 - In Q4 2009 16.1 million purchases were made in Pharmacy Chain 36.6, which is 32.4% lower than during Q4 2008. In Q4 2009 versus Q3 2009 the number of purchases increased by 1.6% (in 2008 – 2.2% decrease in the same compared period).
- In 2009 average check across the network stood at RUR 236, in Moscow – RUR 338, an increase of 12.5% and 12.9% respectively in ruble terms.
 - In Q4 2009 versus Q4 2008 average check across the network stood at RUR 245, in Moscow – RUR 346, an increase of 8.9% and 10.2% respectively in ruble terms.
- Average sales floor size in Q4 2009 is 62.5 sq meters, an increase of 1.6% versus Q4 2008.

PRIVATE LABEL:

- In 2009 private label sales reached RUR 1 127.9 mln, which represents a 29.5% growth in ruble terms compared to 2008.
 - In Q4 2009 private label sales reached RUR 287.4 mln, which represents a 0.8% decrease in ruble terms compared to Q4 2008.
- In 2009 share of private label sales reached 7.1%.
 - In Q4 2009 share of private label sales reached 7.9%;
- Number of SKUs has increased by 17.6% from 698 at the end of 2008 to 821 by the end of 2009.

LIKE-FOR-LIKE SALES IN COMPARABLE STORES³:

As of the end of Q4 2009, the Company operates 850 comparable stores representing 95.0% of sales and 91.0% of traffic in the retail unit in Q4 2009.

L-F-L sales reduction in these stores reached 21% as compared to Q4 2008 while traffic decreased by 26%:

Business Unit	Number of comparable stores	L-F-L sales growth in Q4 2009, RUR	Average check growth in Q4 2009, RUR
1. Central Russia	287	- 14%	7%
2. Regions	563	-28%	3%
Total:	850	- 21%	6%

³ Comparable stores are defined as stores:

- Opened or acquired 24 months from the current reporting period, and
- Neither rebranded nor reformatted or significantly changed during the last 24 months, and
- Not closed in the current reporting period.

During 2009 L-f-L sales represented 88.4% of total sales and L-f-L traffic represented 87.2% of traffic in the retail unit during 2009.

L-F-L sales reduction reached 17% as compared to 2008, while traffic decreased by 25% during 2009:

Business Unit	Number of comparable stores	L-F-L sales growth in 2009, RUR	Average check growth in 2009, RUR
1. Central Russia	287	- 9%	11%
2. Regions	563	-23%	8%
Total:	850	- 17%	11%

DEBT:

According to the management accounts as of the end of 2009, the total Group's financial debt (in ruble terms and including arrears of interest) equaled to RUR 7 619.7 mln, of which Retail debt is RUR 6 666.7 mln⁴.

#

For further information please refer to:

Natalia Kharchevnikova
IR Manager
Management company «Pharmacy Chain 36,6»

kharchevnikova.n.g@366.ru
tel. (+7 495) 797 86 81 ext.17-63

Svetlana Khaltanova
PR Manager
Management company «Pharmacy Chain 36,6»

khaltanova.s.s@366.ru
tel. (+7 495) 797 86 86 ext.19-19

Or to the web-site of the company:

www.pharmacychain366.ru
ir@oao366.ru

Notes to the editor:

Pharmacy Chain 36.6 is the first public national health and beauty retailer listed on the "B" list on the RTS (ticker: APTK) and off-list on the MICEX. The Company's market capitalization as of 14.04.2010 totaled USD 380.0 million (according to RTS).

OAO Veropharm, the company's generics subsidiary, is one of Russia's top five pharmaceutical manufacturers (according to Pharmexpert research). Veropharm's shares are traded in the "B" list on the RTS (ticker: VRPH) and off-list on MICEX (ticker: VRFM). OAO Veropharm's market capitalization as of 14.04.2010 was USD 380.0 million (according to RTS).

ZAO Apteki 36.6 is one of the founding members of the Russian Association of Pharmacy Chains (RAPC).

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION AND IS NOT AN OFFER TO SELL OR AN INVITATION TO MAKE OFFERS TO PURCHASE ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document should not be considered a public offering of securities in the United States. Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933 as amended (the "Securities Act") and may not be offered or sold in the United States or to US persons.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom and (b) persons in the United Kingdom who have (i) professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (the "Order") or (ii) high net worth companies and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49(2) of the Order (all such persons specified in clauses (a) and (b) and together being referred to as "relevant persons"). Any securities referred to in this press release and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

⁴ growth of the Retail debt in Q4 2009 versus Q3 2009 (under IFRS) is due to the fact that in December 2009 part of the Consortium of the banks in Glazar joint venture was restructured into financial debt of Pharmacy Chain 36.6.